Human absorbed dose estimation for a new ¹⁷⁵Yb-phosphonate based on rats data: Comparison with similar bone pain palliation agents

In this work, the absorbed dose to human organs for ¹⁷⁵Yb-BPAMD was evaluated based on the biodistribution studies in rats. The results showed that the bone surface would receive the highest absorbed dose after injection of ¹⁷⁵Yb-BPAMD with 13.32 mGy/MBq, while the other organs receive insignificant absorbed dose. Also, the comparison of ¹⁷⁵Yb-BPAMD with other therapeutic phosphonate complexes demonstrated noticeable characteristics for this new agent. Generally, based on the obtained results, ¹⁷⁵Yb-BPAMD can be considered as a promising agent for bone pain palliative therapy in near future. - Highlights: • ¹⁷⁵Yb-BPAMD complex was prepared in high radiochemical purity (>97%, ITLC). • The highest absorbed dose for ¹⁷⁵Yb-BPAMD is observed in the bone (13.32 mSv/MBq). • All tissues receive insignificant absorbed dose in comparison with bone tissue. • ¹⁷⁵Yb-BPAMD has noticeable characteristics compared to the similar complexes. • ¹⁷⁵Yb-BPAMD can be considered as a promising agent for bone pain palliative therapy.